Article

Study to explore Fuchs' dystrophy genetics

Cleveland-Twenty-three sites will collect data for anationwide study on the genetics of Fuchs' endothelial cornealdystrophy (FECD), which afflicts about 1% of the generalpopulation.

Cleveland-Twenty-three sites will collect data for a nationwide study on the genetics of Fuchs' endothelial corneal dystrophy (FECD), which afflicts about 1% of the general population.

Researchers explore the genetic causes of the disease by collecting data from FECD patients and their family members.

Identification of the genes that may contribute to the development of FECD would be useful for family counseling; studying disease progression; implementation of corneal transplant surgery, if severe; and ultimately, gene modulation and therapy to delay or prevent its progression.

Investigators from the Vision Research Coordinating Center and the department of epidemiology and biostatistics at University Hospitals of Cleveland and Case Western Reserve University School of Medicine will conduct the study, which is funded by a 5-year grant from the National Eye Institute of the National Institutes of Health. The FECD Genetics Multicenter Study will be headquartered at University Hospitals and Case.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.